Table 1.
Baseline patient and tumor characteristics of the study cohort.
| Characteristics | N | % |
|---|---|---|
| Total | 38 | 100 |
| Gender | ||
| Male | 33 | 86.8 |
| Female | 5 | 13.2 |
| Age, median (range), year | ||
| At diagnosis | 47 (20–66) | |
| At CapTem initiation | 48 (23–66) | |
| Inheritance | ||
| Sporadic | 36 | 94.7 |
| Familial (MEN1) | 2 | 5.3 |
| Functional status | ||
| Nonfunctioning | 34 | 89.5 |
| Functioning | 4 | 10.5 |
| TNM | ||
| III | 3 | 7.9 |
| IV | 35 | 92.1 |
| Ki67 index | ||
| <3% | 0 | 0 |
| 3%–20% | 29 | 76.3 |
| >20% | 9 | 23.7 |
| Mitosis (2 mm2) | ||
| <2 | 2 | 5.3 |
| 2–20 | 29 | 76.3 |
| >20 | 1 | 2.6 |
| NA | 6 | 15.8 |
| MGMT expression | ||
| Negative | 1 | 2.6 |
| Week | 1 | 2.6 |
| Moderate | 11 | 28.9 |
| Strong | 16 | 42.1 |
| NA | 9 | 23.7 |
| Metastatic sites | ||
| None | 1 | 2.6 |
| Lymph nodes | 30 | 78.9 |
| Pleura | 16 | 42.1 |
| Pericardium | 8 | 21.1 |
| Lung | 7 | 18.4 |
| Pancreas | 7 | 18.4 |
| Liver | 3 | 7.9 |
| Bone | 27 | 71.1 |
| Prior resective surgery | ||
| Yes | 17 | 44.7 |
| No | 21 | 55.3 |
| Prior radiotherapy | ||
| Yes | 14 | 36.8 |
| No | 24 | 63.2 |
| Previous systemic treatments | ||
| No prior treatment | 18 | 47.4 |
| SSA | 1 | 2.6 |
| Molecular-targeted agents | 4 | 10.5 |
| Everolimus | 2 | 5.3 |
| Surufatinib | 2 | 5.3 |
| Chemotherapy | 18 | 47.4 |
| Taxel & Cisplatin | 1 | 2.6 |
| Cyclophosphamide & Pirarubicin & Cisplatin | 1 | 2.6 |
| Docetaxel & Cisplatin | 1 | 2.6 |
| Etoposide & Cisplatin | 14 | 36.8 |
| Paclitaxel & Carboplatin & Bevacizumab | 1 | 2.6 |
| CapTem line of treatment | ||
| First line (naïve) | 18 | 47.4 |
| ⩾Second line (pretreated) | 20 | 52.6 |
CapTem, capecitabine and temozolomide; MGMT, O6-methylguanine DNA methyltransferase; SSA, somatostatin analog; TNM, tumor-node-metastasis.